Awareness of heart disease risk factors and personal risk after a prior cardiovascular event
Official title: Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention: A Comparison Between Women and Men
Run by Istituti Clinici Scientifici Maugeri SpA · NCT07521436 · Data updated 2026-11-12
This survey will see if adults with prior atherosclerotic cardiovascular disease understand general and sex-specific risk factors and how at risk they feel of future events.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Istituti Clinici Scientifici Maugeri SpA Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | April 10, 2026 |
| Main results expected | January 10, 2027 |
| Study ends | January 10, 2027 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT07521436 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with documented atherosclerotic cardiovascular disease (ischemic heart disease, cerebrovascular atherosclerotic disease, peripheral arterial disease, or atherosclerotic aortic disease) who can give informed consent are eligible.
✕Probably not a fit
People without established atherosclerotic cardiovascular disease, those with non-qualifying cerebrovascular events (e.g., primary intracerebral hemorrhage), or those unable to consent are not eligible and will not directly benefit from this survey.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational survey enrolling adults with established atherosclerotic cardiovascular disease to measure knowledge of general and sex/gender-specific risk factors and perceived risk of recurrent events. Participants complete questionnaires about their awareness of risk factors (including sex-specific conditions) and their perception of future cardiovascular risk. The study compares responses between women and men and examines whether having had a prior event is associated with changes in knowledge or risk perception. No medical or behavioral interventions are provided as part of the project.
Why it matters
Potential benefit: If gaps in knowledge or risk perception are identified, the findings could guide targeted education and follow-up strategies to improve prevention and adherence.
How similar studies have gone: Previous studies in primary prevention have shown low awareness of cardiovascular risk—especially among women—but there are limited or no data specifically focused on awareness and risk perception in secondary prevention, making this a novel, gap-filling effort.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Male or female participants aged ≥ 18 years at the time of signing informed consent. * Individuals with atherosclerotic cardiovascular disease (ASCVD), defined as at least one of the following: * Ischemic heart disease (e.g., documented myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or ≥50% coronary stenosis in at least two coronary territories); * Cerebrovascular disease (e.g., documented ischemic stroke; transient ischemic attack, primary intracerebral hemorrhage, and subarachnoid hemorrhage are not qualifying conditions; carotid stenting or endarterectomy); * Peripheral arterial disease (e.g., peripheral arterial intervention, stent placement, surgical revascularization, lower limb amputation due to obstructive disease, or intermittent claudication with ABI \<0.90 in the past 12 months); * Atherosclerotic aortic disease (e.g., abdominal or descending thoracic aortic aneurysm). * Signed informed consent. Exclusion Criteria: * Inability or difficulty in completing the questionnaires in Italian and/or functional illiteracy. * History of or current severe psychiatric disorder that could compromise the reliability of questionnaire responses. * Refusal or withdrawal of informed consent.
Where it's running
-
Istituti Clinici Scientifici IRCCS Maugeri
Milan, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease
This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.
-
Petrelintide for weight loss in people with overweight/obesity and heart disease
This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.
-
VERVE-102 for adults with or at high risk for heart disease
This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.
-
Clazakizumab for adults with high hsCRP at risk for a heart event
This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.
-
Improving Care for underserved older Black patients with cardiovascular and other chronic conditions
This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.
-
4D MRI parameters linked to cardiovascular and cancer disease outcomes
This study tests whether 4D MRI measurements can predict how cardiovascular diseases and cancer will progress in adults undergoing routine cardiac MRI at a single Korean hospital.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.